Role of serum adropin measurement in the assessment of insulin resistance in obesity.


Journal

Journal of investigative medicine : the official publication of the American Federation for Clinical Research
ISSN: 1708-8267
Titre abrégé: J Investig Med
Pays: England
ID NLM: 9501229

Informations de publication

Date de publication:
10 2021
Historique:
accepted: 13 04 2021
pubmed: 22 5 2021
medline: 4 2 2022
entrez: 21 5 2021
Statut: ppublish

Résumé

Obesity has recently been mentioned as a metabolic pandemic in developed and developing countries and is an important known risk factor for type 2 diabetes and cardiovascular diseases. The main mechanism responsible for obesity is insulin resistance. Adropin is a peptide-structured regulatory hormone that is suggested to play a role in insulin resistance and metabolic regulation. We aimed to evaluate the associations of serum adropin with insulin resistance and clarify the factors affecting serum adropin concentrations. The study included 50 obese patients and 22 healthy controls. Patients with chronic disease and drug use history were excluded. Serum adropin and other metabolic parameters were obtained after overnight fasting. ELISA was used to measure serum adropin concentrations. The homeostatic model assessment-insulin resistance (HOMA-IR) index was used to calculate insulin resistance. Insulin resistance was defined as HOMA-IR >2.5. Serum adropin values were found to be low in the obese otherwise healthy patient group (p<0.001). Linear regression analysis revealed that age, body mass index (BMI), waist circumference (WC), high-density lipoprotein cholesterol, fasting glucose, and HOMA-IR affect serum adropin level. In multiple regression analysis, age is the most significant factor affecting serum adropin concentration. Serum adropin concentrations were negatively correlated with BMI, WC, diastolic blood pressure, fasting glucose, and insulin. Serum adropin concentrations were low in obese patients and the optimum cut-off point for adropin to indicate HOMA-IR at 2.5 is 216.7 ng/L. The findings suggest that serum adropin may contribute to the regulation of glycolipid metabolism and insulin resistance in obese patients.

Identifiants

pubmed: 34016737
pii: jim-2021-001796
doi: 10.1136/jim-2021-001796
doi:

Substances chimiques

Blood Glucose 0
Cholesterol, LDL 0
Enho protein, human 0
Insulin 0
Intercellular Signaling Peptides and Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1318-1323

Informations de copyright

© American Federation for Medical Research 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Hande Erman (H)

Internal Medicine, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey handeerman@yahoo.com.

Ali Ozdemir (A)

Internal Medicine, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey.

Mustafa Erinc Sitar (ME)

Clinical Biochemistry, Maltepe Universitesi Tip Fakultesi, Istanbul, Turkey.

Seher Irem Cetin (SI)

Internal Medicine, Gaziosmanpaşa Taksim Eğitim ve Araştırma Hastanesi, Istanbul, Turkey.

Banu Boyuk (B)

Internal Medicine, Istanbul Dr Lutfi Kirdar Kartal Egitim ve Arastirma Hastanesi, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH